Abstract Changes over 50 years of research on antipsychotics in schizophrenia have
occurred. A scientometric synthesis of such changes over time and a measure of …

Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Importance The effectiveness of antipsychotic polypharmacy in schizophrenia relapse
prevention is controversial, and use of multiple agents is generally believed to impair …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Treatment-resistant schizophrenia (TRS) occurs in approximately 30% of individuals
diagnosed with schizophrenia. The identification and management of TRS in clinical …

Treatment-resistant schizophrenia (TRS) represents a major clinical challenge. The broad
definition of TRS requires nonresponse to at least 2 sequential antipsychotic trials of …

We summarized and compared meta-analyses of pharmacological and non-
pharmacological interventions targeting physical health outcomes among people with …

Negative symptoms of schizophrenia remain a major therapeutic challenge. The progress in
the conceptualization and assessment is not yet fully reflected by treatment research …

Importance Limited treatment responses in schizophrenia prompted the testing of combining
an antipsychotic drug treatment with a second psychotropic medication. A comprehensive …